Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site

Summary

Tissue factor (TF) antagonists targeting the factor VII (FVII) binding domain have been shown to interrupt acute vascular thrombus formation without impairing haemostasis in non-human primates. In this study, we evaluate whether a human/mouse chimeric monoclonal antibody (ALT-836, formerly known as Sunol-cH36) blocking the factor X/factor IX (FX/FIX) binding site of tissue factor could achieve similar clinical benefits in an arterial thrombosis model induced by surgical endarterectomy in chimpanzees. In this model, sequential surgical endarterectomies on right and left superficial femoral arteries were performed 30 days apart in five chimpanzees. A bolus (1 mg/kg) of ALT-836 was injected intravenously immediately preceding the restoration of flow in the endarterectomised femoral artery. Pre-surgical labelling of autologous platelets using ¹¹¹In-Oxine and post-surgical gamma camera imaging of ¹¹¹In-platelet deposition at endarterectomy sites was performed. The manipulated arterial segments were harvested for patency analysis 30 days following surgery. The results indicate that ALT-836 was highly effective at reducing acute vascular thrombosis, with no significant variations in surgical blood loss and template-bleeding time in the treated group compared to the control animals. These data suggest that ALT-836 is an effective and safe antithrombotic agent in preventing TF-initiated vascular thrombogenesis without compromising haemostasis.

Keywords

Tissue factor / factor VII - animal models - arterial thrombosis - coagulation inhibitors

• References

• 1 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 2 Harker LA. et al. Novel antithrombotic agents. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.P. Lippincott; 1994. pp. 1638-1660.
• 3 Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
• 4 Falk E. et al. Coronary plaque disruption. Circulation 1995; 92: 657-671.
• 5 Krishnaswamy S, Field KA, Edgington TS. et al. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 1992; 267: 26110-26120.
• 6 Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.
• 7 Harker LA. et al. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997; 78: 736-741.
• 8 Weitz JI. et al. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 234S-256S.
• 9 Shirk RA, Vlasuk GP. Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007; 27: 1895-1900.
• 10 Himber J. et al. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-1149.
• 11 Harker LA. et al. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26: 76-82.
• 12 Neuenschwander PF, Morrissey JH. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J Biol Chem 1994; 269: 8007-8013.
• 13 Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25: 47-56.
• 14 Versteeg HH. et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190-199.
• 15 Stinson JR. et al. Generation of single-chain antibody fragments by PCR. In: PCR Strategies. Academic Press; San Diego: 1995: 300-312.
• 16 Broze GJ. Jr., et al. Purification of human brain tissue factor. J Biol Chem 1985; 260: 10917-10920.
• 17 Barenholz Y. et al. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-2810.
• 18 Neuenschwander PF. et al. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa activity. Thromb Haemost 1993; 70: 970-977.
• 19 Broze GJ. Jr., et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
• 20 Fair DS, MacDonald MJ. Cooperative interaction between factor VII and cell surface-expressed tissue factor. J Biol Chem 1987; 262: 11692-11698.
• 21 Lumsden AB. et al. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood 1993; 81: 1762-1770.
• 22 Kelly AB. et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012.
• 23 Harker LA. et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-1844.
• 24 Kotze HF. et al. Kinetics of In-111-platelets in the baboon: I. Isolation and labelling of a viable and representative platelet population. Thromb Haemost 1985; 53: 404-407.
• 25 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ke-tone. Proc Natl Acad Sci USA 1988; 85: 3184-3188.
• 26 Suleymanov OD. et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-1121.
• 27 Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265: 327-336.
• 28 Ruf W. et al. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 16256.
• 29 Morrow DA. et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005; 26: 682-688.
• 30 Welty-Wolf KE. et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006; 290: L21-31.
• 31 Bruggemann M. et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166: 1351-1361.
• 32 Steffel J. et al. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
• 33 Kirchhofer D. et al. Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies. Thromb Haemost 2000; 84: 1072-1081.
• 34 Shaw AW. et al. The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 2007; 282: 6556-6563.
• 35 Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007; 05: 1097-1105.
• 36 Shobe J. et al. Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. J Biol Chem 1999; 274: 24171-24175.
• 37 Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF:VIIa complex is a potent anticoagulant in plasma. Thrombosis and Haemostasis 1991; 66: 529-533.
• 38 Faelber K. et al. The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites. J Mol Biol 2001; 313: 83-97.
• 39 Huang M. et al. The meachanism of inhibitory antibody on TF-initiated blood coagulation revealed by crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. J Mol Biol 1998; 275: 873-894.
• 40 Ohto U. et al. Crystal structure of a humanized Fab fragment of anti-tissue factor antibody in complex with tissue factor. J Synchrotron Radiat 2004; 11: 105-108.
• 41 Sambola A. et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977.
• 42 Felmeden DC. et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400-405.
• 43 Soejima H. et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-2913.
• 44 Ardissino D. et al. Tissue-factor antigen and activity in human coronary athero-sclerotic plaques. Lancet 1997; 349: 769-771.
• 45 Marmur JD. et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-1232.
• 46 Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-384.
• 47 Simak J. et al. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost 2006; 04: 1296-1302.
• 48 Chironi GN. et al. Endothelial microparticles in diseases. Cell Tissue Res 2009; 335: 143-151.
• 49 Dignat-George F. et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-673.
• 50 Shet AS. et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102: 2678-2683.
• 51 Diamant M. et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
• 52 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-196.
• 53 Butenas S. et al. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
• 54 Bogdanov VY. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 09: 458-462.
• 55 Erhardtsen E. et al. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001; 41: 880-885.